May 2026 Research Update

This month included a small, early clinical report where people with type 1 Gaucher disease taking eliglustat showed improvements in both a blood marker and in organ size over 1 year. The study also described few side effects, although the small number of participants means uncommon problems could be missed. Together, this adds another real-world data point that eliglustat can move multiple Gaucher-related measures in the expected direction in some patients. [1]

In this single-arm study of 5 adults treated for 52 weeks, lyso-GL1 (a Gaucher-related blood marker) went down, hemoglobin and platelet counts went up, and liver and spleen volumes got smaller. One person reported mild nausea and reduced appetite that went away within 2 days, and no other adverse events were reported in the summary. All participants were described as CYP2D6 extensive metabolizers, which matters because this can affect how the body processes eliglustat, but the study did not include other metabolizer types. [1]

For patients and caregivers, this study mainly adds incremental evidence that eliglustat can be followed using several familiar measures at once, including lyso-GL1, blood counts, and liver and spleen size. Because there was no comparison group and only 5 participants, the report cannot tell how these changes compare with no treatment or with other treatments, or how consistent results would be across broader Gaucher populations. This is most useful as early clinical research that supports ongoing study, rather than something that settles questions about benefits or risks for everyone. [1]

Two human studies this month focused on what can change over time in Gaucher disease even outside a treatment trial: neurologic outcomes with aging, and biomarker changes during periods without treatment. Put together, they reinforce that Gaucher disease can have important long-range differences between people, and that a single blood marker may not always move in lockstep with common lab measures like hemoglobin and platelets. This month does not simplify Gaucher monitoring into one number, but it does make the expected directions of change in some situations clearer. [2] [3]

In the ICGG Gaucher Registry analysis of 1,618 people with type 1 Gaucher disease, Parkinson disease (PD) and a broader parkinsonian syndrome were reported more often at older ages, with PD prevalence reaching 12.2% by age 80. The study also reported a qualitative genotype difference: people with 2 mild GBA1 variants had a lower reported risk of PD and parkinsonian syndrome than those with 1 mild variant. This helps place neurologic concerns in an age-related, long-term context, while also showing that risk is not uniform across all genotypes. [2]

In a separate retrospective longitudinal study using a large clinic database, lyso-Gb1 changes during untreated periods were usually small, but increases were more common than declines. In the main untreated-state analysis (272 people with at least 2 untreated visits), 36.0% had an increase of at least 50 ng/mL, while 12.9% had a decline of at least 50 ng/mL, and many stayed within plus or minus 50 ng/mL. The study also noted that lyso-Gb1 could rise even when hemoglobin and platelet counts did not change beforehand, suggesting the marker may sometimes shift before routine blood counts do, or may reflect additional factors not captured in those labs. [3]

For families, these studies mainly add context for planning and expectations across years rather than weeks. The registry data suggests that movement and other neurologic symptoms become more common with age in type 1 Gaucher disease, and that the underlying GBA1 genotype category may relate to different risk levels, though the study relied on registry-recorded diagnoses and may miss or misclassify some cases. The lyso-Gb1 study helps clarify that this biomarker can be stable for many people without treatment, but it can also rise in a meaningful subset, sometimes without obvious changes in common blood counts, which matters for how patients interpret a changing lab result over time. These are observational findings that may matter now for understanding what monitoring results can mean, but they do not by themselves prove why changes happen or what any one person will experience. [2] [3]

This month, several studies stayed in the research space but pointed in a similar direction: Gaucher disease biology may involve multiple stress and immune pathways, and better tools are being built to measure and model them. The work ranged from cell experiments to computational modeling and new lab measurement methods. Together, these studies do not change what is known in patients right now, but they make the research picture more detailed and testable. [4] [5] [6] [7] [8]

In laboratory studies of neuronopathic Gaucher disease models, blocking the c-Abl and RIPK3 signaling pathway was reported to restore healthier mitochondrial function and improve mitophagy (the process cells use to remove damaged mitochondria). These results were seen in patient-derived fibroblasts with GBA1 mutations and in rat neurons where the Gaucher-like state was induced by inhibiting glucocerebrosidase. This adds a specific, testable pathway linking Gaucher-related cell stress to mitochondrial quality control, while staying clearly at the lab stage rather than showing clinical benefit. [4]

An exploratory RNA sequencing study compared macrophages grown from blood cells of 2 identical twins with type 1 Gaucher disease and 2 healthy controls, and reported a shared Gaucher-related pattern of immune activation and lysosomal stress. The two twins differed in interferon-related gene activity, but this difference was small and did not remain statistically significant after correcting for many tests. This supports the idea that non-genetic factors may shape how Gaucher disease shows up even when the GBA1 gene background is the same, but the sample was too small to draw firm conclusions. [5]

Two method-focused studies aimed to improve how Gaucher-related processes are measured and simulated. One validated a sensitive LC-MS/MS lab method to measure 11 related lipid molecules in cells, plasma, and brain tissue, which is the kind of tool needed for future drug and biomarker studies. Another built a multiscale computer model of how macrophages engulf red blood cells, and in Gaucher-like perturbations the model showed reduced inhibitory signaling through the CD47-SIRPa-SHP1 pathway and different engulfment behavior, offering a framework to test "what-if" scenarios in silico. [7] [6]

A systematic review focusing on Asian populations highlighted how varied GBA1 genetic changes are across countries and regions, which can affect how often different Gaucher presentations are seen. Across 419 patients with usable genotype-phenotype data, 162 distinct genotypes were identified, and L444P was the most prevalent variant (pooled proportion 0.46), while N370S was common in parts of West Asia but rare or absent in East Asian countries. This helps explain why Gaucher genetics described in one region may not match what families see in another region. [8]

For patients and caregivers, these studies mainly matter as groundwork for future tests and treatments rather than something that changes care now. The cell and computer studies help narrow down specific pathways (like mitochondrial cleanup problems or red blood cell clearance signals) that researchers can target and measure, but they do not show that changing these pathways will improve symptoms in people. The lab method paper and the genetics review help clarify why measurement quality and population genetics matter, since accurate lipid tracking and region-specific genetic patterns can shape future research and how results apply to different communities. The biggest uncertainty is how well these lab and modeling findings will translate into reliable markers or new therapies in clinical studies. [4] [5] [6] [7] [8]

This month included a small set of reported fetal/perinatal Gaucher disease cases that adds detail to how severe early-onset forms can appear before birth. Across the cases, the prenatal picture was dominated by hydrops (fluid buildup), and diagnosis was supported by findings at autopsy showing Gaucher cells in multiple organs. Because this is a case series, it describes what happened in these pregnancies rather than predicting what will happen in others. [9]

In 4 fetuses, hydrops was detected prenatally after 24 weeks of gestation and led to pregnancy termination in the reported cases, with autopsy often showing enlarged liver and spleen. Gaucher cells were found in multiple organs, and brain involvement was reported in 2 cases. Only 1 case was genetically confirmed, and the authors noted that more reporting is needed to connect specific gene changes to specific prenatal findings. [9]

For families, this case series mainly adds descriptive information that may be relevant in prenatal or reproductive discussions, especially when there is known Gaucher risk in a family. The report clarifies that prenatal hydrops appearing after mid-pregnancy and multi-organ Gaucher cell findings can occur in fetal/perinatal Gaucher disease, but it does not provide reliable probabilities or a clear gene-based prediction because most cases lacked genetic confirmation. This information is mainly useful for understanding what has been reported in rare, severe presentations, and what remains uncertain is how strongly these findings tie to specific genotypes. [9]